Neurocognitive function and neuroimaging markers in virologically suppressed HIV- positive patients randomised to ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial
نویسندگان
چکیده
MRC-Clinical Trials Unit at UCL, London, UK UCL Research Department of Infection and Population Health, London, UK Neuroradiology Academic Unit, UCL Department of Brain Repair & Rehabilitation, Institute of Neurology, London, UK NMR Research Unit, UCL Department of Neuroinflammation, Queen Square MS Centre, Institute of Neurology, London, UK Brighton and Sussex University Hospitals NHS Trust, Brighton, UK Royal Free Hospital, London, UK Royal Berkshire Hospital, Reading, UK Imperial College London, UK Yong Loo Lin School of Medicine, National University of Singapore, Singapore
منابع مشابه
Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy
BACKGROUND In patients who remain virologically suppressed in plasma with triple-drug ART a switch to protease inhibitor monotherapy maintains high rates of suppression; however it is unknown if protease inhibitor monotherapy is associated to a higher rate of neurocognitive impairment. METHODS In this observational, cross-sectional study we included patients with plasma virological suppressio...
متن کاملNext generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy
BACKGROUND The PIVOT trial examined whether patients with suppressed viral load on combination antiretroviral therapy could be safely switched long-term to ritonavir-boosted protease inhibitor (PI) monotherapy. The main trial publication reported that only one of 296 patients allocated to PI monotherapy experienced a loss of drug options due to protease mutations (identified by local Sanger seq...
متن کاملMonotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study.
This study compared the cost-efficacy ratios of lopinavir/ritonavir monotherapy (LPV/r-MT) and of standard of care in virologically suppressed HIV-infected patients. The results of the efficacy and safety analyses are presented. We conducted a multicentre, randomised, open-label trial of HIV-infected adults on stable treatment, with HIV- RNA <50 copies/mL, randomised to continue the ongoing reg...
متن کاملBoosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting
While the introduction of combination highly active antiretroviral therapy (HAART) regimens represents an important advance in the management of human immunodeficiency virus (HIV)-infected patients, tolerability can be an issue and the use of several different agents may produce problems. The switch of combination HAART to ritonavir-boosted protease inhibitor (PI) monotherapy may offer the oppo...
متن کاملEffectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis
BACKGROUND The unparalleled success of combination antiretroviral therapy (cART) is based on the combination of three drugs from two classes. There is insufficient evidence whether simplification to ritonavir boosted protease inhibitor (PI/r) monotherapy in virologically suppressed HIV-infected patients is effective and safe to reduce cART side effects and costs. METHODS We systematically sea...
متن کامل